Understanding the effectiveness of a CGRP mAb against ligand in patients not responding sufficiently to a CGRP mAb against the receptor may increase the treatment opportunities of these highly disabled patients and improve the understanding of the effect of modulating the CGRP at different levels of its pathways in migraine. Here, CALCA is linked to migraine disorder.